Hydrogel/Polymersome-based Subunit Vaccines in the Fight Against COVID-19

Información del proyecto

HYPOVACC

Identificador del acuerdo de subvención: 101030481

DOI

10.3030/101030481

Proyecto finalizado el 31 Enero 2024

Fecha de la firma de la CE 22 Marzo 2021

Fecha de inicio 1 Junio 2021

Fecha de finalización 31 Enero 2025

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 257 619,84

Aportación de la UE

€ 257 619,84

Coordinado por

UNIVERSITE DE BORDEAUX
France

Periodic Reporting for period 2 - HYPOVACC (Hydrogel/Polymersome-based Subunit Vaccines in the Fight Against COVID-19)

Período documentado: 2023-06-01 hasta 2024-05-31

Resumen del contexto y de los objetivos generales del proyecto

The development of effective vaccine technologies for the fight against severe infectious diseases has been one of the most successful global health interventions in history. Yet, the threat of future and ongoing pandemics arisen from viruses such as the SARS-CoV-2 virus complexifies the design of readily applicable vaccine formulations. Over the last three years, the COVID-19 pandemic has quickly evolved with the emergence of multiple variants, including the immune evasive variant Omicron that can escape the immune response and participates in reducing vaccine effectiveness. To face the overall challenges of the pandemic, Moderna and Pfizer-BioNTech mRNA vaccines have been authorized for emergency use. While this technology is revolutionary, it suffers from strict storage conditions as well as lack of protection over long timescales and against variants, which lead to burdensome vaccination schedules as well as expensive manufacturing and distribution. There is therefore a need for more protective, potent, and easily manufacturable vaccines to enhance immunity and decrease the burden of patient compliance.
The project HYPOVACC aims to overcome these issues by designing cost-effective vaccine systems able to effectively protect against a variety of viruses belonging to the family of coronaviruses such as SARS-CoV-2 or potential future related viruses. These efforts envision to decrease the cost of manufacturing/distribution, and number of vaccinations, reinforcing therefore worldwide vaccine equity and patient compliance.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

We successfully designed vaccine delivery systems able to significantly enhance the protection against the SARS-CoV-2 Omicron variant as well as other coronaviruses in a same vaccine formulation. Short-term and long-term protection over several months have been validated in rodents.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The HYPOVACC project outperforms the state of start through the design of potent vaccine delivery systems for enhancing the protection against current and future coronaviruses. More importantly, this newly designed vaccine formulation is easily formed with cost-effective and clinically approved materials, reinforcing its translation into the clinic. Moreover, this system can be easily modulated to be applied to a variety of challenging infectious diseases such as HIV, malaria, or flu, participating therefore in the reinforcement of Global Health research.

figure-mc-publication.png